CBD & Autism

Improvement in Quality of Life

CBD oil benefits are proving to positively impact children diagnosed with Autism Spectrum Disorder (ASD). Since there has been at least a 3-fold increase during the last 3 decades, parents are desperately seeking out alternative therapeutic treatments. This has led to recent studies which have concluded that CBD oil without THC is effective in enhancing the quality of life for refractory behavioral problems in children with ASD. The positive changes are drastic and include a positive mood, the ability to dress and shower independently, improvement in sleep and good concentration during their active treatment on CBD oil. Other studies reported seeing positive results from CBD oil treatment on symptoms like anxiety, restlessness, aggression, panic, tantrum and self-injurious behavior.

Science Behind CBD Oil and Autism Spectrum Disorder

It is very exciting to read that new CBD studies are continuing to pop-up and increasing in frequency, as people are seeking to understand the rise in the effectiveness of CBD oil and health. The patients in the studies specific to researching CBD Oil and autism were put on a strict regimen consuming of CBD oil three times daily with 30% CBD and 1.5% THC. A 2013 study conducted by Dr. Csaba Foldy of Stanford University Medical School found that the neuroligin-3 protein is mutilated in individuals with autism and interferes with the signaling from cannabinoid receptors. The CB1 and CB2 receptors are inhibited, and the CBD oil stimulation in these receptors may aid in symptoms. CBD works by actively binding to CB2 receptors and this stimulation of the endocannabinoid system appears to help alleviate some of the symptoms associated with ASD. These studies are groundbreaking and

Based on studies, CBD oil helps autism by easing the stress of overstimulation and social interaction, by regulating synapse signaling. A study of Cannabidiol Based Cannabis in Children with Autism Autism Study April 9, 2018 showed strong results following treatment for a significant decrease in behavioral outbreaks (on the CGIC scale) in 61% of patients. That was only one of numerous positive studies that are forcing the medical industry to finally take notice and advanced new studies are continuing to form.